OR WAIT null SECS
Antiretroviral drugs can bring patients back to life. But how do pharma's products get to patients at the heart of the world's biggest health disaster?
The Medicare Prescription Drug Benefit doesn't begin until next year. But for pharma, a key deadline is right around the corner.
The Sampling Subsidy
Nancy Lurker and Bob Caprara
Sampling is an enormous part of pharmaceutical marketing. But no one has been sure what happens to samples—until now.
The Rise and Fall of Pharma Reputations
Doretta W. Gasoreks and Jeffrey T. Resnick
Rating Research LLC
In a memorably bad year for pharma, a few companies still managed to shine.
Bridging the Gap
Lynda C. McDermott and Esther Fleischhacker
It's not the deal that scuttles most strategic alliances. It's the culture. The key to success: Know your partner (and yourself).
Pharma's tsunami aid
Do people still trust drugs?
Fran DeGrazio of West Pharmaceutical Services on packaging for biologics.
Safety is dominating the debate over drug regulation. And that's not all good.
British royalty: Cambridge Antibody Technologies wins its case against Abbott.
A successful leader has to be a full-time teacher.
Sander A. Flaum
Direct to Consumer
Direct mail is once again winning favor in the pharma marketing mix—just be sure to customize it.
Marketing to Professionals
Do readers care who sponsors studies published in medical journals? Editors give their two cents.
Blogger Matthew Holt cuts through the hype of disease management.
There are no great, cheap, and easy metrics out there to measure CME. But here's how to make what's available work for you.
The industry's operating paradigm is changing. And PR needs to change with it.
From the Editor
AIDS in Africa: Don't think of it as a market. Think of it as a critique of the industry.
FDA is great at approving new drugs. But it needs to be great at some other jobs, too.
Jonathan Seltzer, MD
Applied Clinical Intelligence
Calendar of Events